Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Chengdu MedGenCell

Company type: Therapeutics

Main focus: Gene editing for the development of cellular therapies

Company stage: Clinical

Diseases: Haematological and solid tumours

Genome-editing tool: CRISPR

Funding stage: Private

Location: Chengdu, China

Website: http://www.medgencell.com/

Shanghai IASO Biotechnology develops next-generation CAR-T cell therapies, and uses CRISPR to knock out certain genomic targets to improve the efficacy and safety of its cellular products.

Tags

HashtagChengdu MedGenCell, Co., Ltd.

Company: Chengdu MedGenCell
close
Search CRISPR Medicine